

# Pan-phosphatidylinositol 3-kinase inhibitor Buparlisib demonstrates activity in patients with NHL, particularly in achieving sustained responses in patients with MCL and FL, and an acceptable safety profile



Open-label phase II study



Patients with relapsed or refractory non-Hodgkin lymphoma



100 mg once daily of BKM120 ( pan-class I PI3K inhibitor)



26

Diffuse large B-cell lymphoma



22

Mantle cell lymphoma



24

Follicular lymphoma

## Primary endpoint

Overall response rate  
6-month best overall response

11.5%

22.7%

25.0%

## Secondary endpoints

Progression-free survival, duration of response, overall survival, safety, and tolerability

## Most frequently reported (>20%) any-grade adverse events in the safety population

36.1% hyperglycemia

29.2% depression

36.1% fatigue

27.8% diarrhea

36.1% nausea

25.0% neutropenia

## Most common grade 3/4 adverse events

11.1% hyperglycemia

5.6% neutropenia